Adam Steensberg | BiotechTV

top of page

Jefferies London: Zealand Pharma CEO Adam Steensberg believes that amylins will overtake GLPs as the backbones of obesity treatments in the future

He discusses Zealand's partnership with Roche, and new data that will be coming next year. Plus, the company's partnership with Boehringer on survodutide. Coverage brought to you by

Company News

8 hours ago

A deep-dive discussion on obesity drug development with Zealand Pharma's CEO Adam Steensberg

He highlights Zealand’s three different approaches to obesity: glucagon/GLP-1, GLP-1/GLP-2, and an amylin analog. Plus, he shares his...

Company News

Oct 10, 2024

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page

Jefferies London: Zealand Pharma CEO Adam Steensberg believes that amylins will overtake GLPs as the backbones of obesity treatments in the future

A deep-dive discussion on obesity drug development with Zealand Pharma's CEO Adam Steensberg

Follow BiotechTV

Sponsors

Sponsor Spotlight